Dermatology

Survey Shows Stark Difference in Satisfaction Rates Among Skin Cancer Patients Treated Surgically and Nonsurgically

Retrieved on: 
Wednesday, May 1, 2024
Pain, Mohs surgery, Skin, Risk, Private practice, Commonwealth, Dermatology, Skin cancer, SRT, Patient, Medical imaging

The survey involved 3,915 individuals who had been treated for nonmelanoma skin cancer one or more times.

Key Points: 
  • The survey involved 3,915 individuals who had been treated for nonmelanoma skin cancer one or more times.
  • SkinCure Oncology Chief Executive Officer Kerwin Brandt explained, "With GentleCure, we're providing cancer center level of care in the private practice.
  • Dermatologists across the country are celebrating the introduction of this nonsurgical treatment for the nation's most common cancer type – nonmelanoma skin cancer.
  • While May is Skin Cancer Awareness Month, early-adopter skin specialists in 40 states are already providing the GentleCure Experience to patients who prefer to avoid surgery or for whom surgery is not recommended.

Melanoma Research Alliance Announces $12.6 Million Investment in Cutting Edge Melanoma Research

Retrieved on: 
Wednesday, May 1, 2024
Moles, FDA, Brain, Patient, Investment, Diagnosis, Skin, African Americans, AI, Machine learning, Immunotherapy, Recurrence, Doctor of Philosophy, Research, Skin cancer, Melanoma, Disease, Dermatology, Exercise, Marie Cassidy, MRA, Diet, Neoplasm, Biology, Immune system, Anxiety, Algorithm, Medical imaging

WASHINGTON, May 1, 2024 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the world's leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.

Key Points: 
  • WASHINGTON, May 1, 2024 /PRNewswire/ -- The Melanoma Research Alliance (MRA), the world's leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.
  • "When MRA was founded in 2007, melanoma research was stagnant and treatment options were few.
  • "Melanoma research has made tremendous progress over the last 15 years," said MRA Chief Science Officer Joan Levy, PhD.
  • MRA's investments in rare melanoma research have begun to advance the field's understanding of the biology of these rare melanomas and their molecular differences from cutaneous (skin) melanoma.

DigitCells Unveils Proprietary TWO-D system at AUA 2024, Revolutionizing Pathology Workflows

Retrieved on: 
Wednesday, May 1, 2024
Prostate, American Urological Association, Breast, LIS, Pathology, Intelligence, Digital, Environment, GI, Marie Cassidy, Histology, Acquisition, IMS, AUA, Annual general meeting, Medical director, Dermatology, Overalls, Medical imaging

CHICAGO, May 1, 2024 /PRNewswire-PRWeb/ -- DigitCells, a leading innovator in complete digital pathology solutions and a subsidiary company of GoPath Diagnostics, is excited to announce the launch of its groundbreaking Tissue Workflow Optimization for Digital (TWOD) system for prostate at the upcoming 2024 American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The TWOD system represents a revolutionary leap in pathology workflows, delivering unprecedented efficiency gains and setting a new benchmark in digital pathology."
  • Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics
    The TWOD system streamlines biopsy tissue workflows, significantly enhancing efficiency to meet the demands of today's pathology environment.
  • This process is centrally managed by TWOD's LIS and IMS system which integrates laboratory information and pathology imaging with embedded augmented intelligence and pathology sign-out functions.
  • The TWOD system bridges the gap between histopathology and digital pathology, reducing cost and improving workflow efficiency.

Raheem Mostert, Miami Dolphins, Melanoma Supporter and Advocate, Gets Naked for Melanoma Awareness Month

Retrieved on: 
Wednesday, May 1, 2024
University, Neutrogena, Advocate, Cancer, Skin, Travel, Research, Survival, Miami Dolphins, Veronica, Skin cancer, Melanoma, Disease, Patient, Walgreens, Bristol Myers Squibb, MRF, Merck, Dermatology, Pharmaceutical industry

WASHINGTON, May 1, 2024 /PRNewswire-PRWeb/ -- Decorated Running Back for the Miami Dolphins, Melanoma Supporter and Advocate Joins the Melanoma Research Foundation's #GetNaked Campaign to Promote Melanoma Prevention and Early Detection

Key Points: 
  • The Melanoma Research Foundation (MRF) is pleased to announce the official launch of its annual award-winning #GetNaked campaign in recognition of Melanoma Awareness Month this May.
  • Miami Dolphins running back, Raheem Mostert will serve as this year's #GetNaked campaign spokesperson.
  • WASHINGTON, DC (May 1, 2024) – The Melanoma Research Foundation (MRF) is pleased to announce the official launch of its annual award-winning #GetNaked campaign in recognition of Melanoma Awareness Month this May.
  • To support critical melanoma research in finding effective treatments and a cure for melanoma, donate here .

Vector Consumer Limited Announces Second Acquisition, Dose & Co

Retrieved on: 
Wednesday, May 1, 2024
Pura, NPD, Dose, Health, Wellness, Human, Female, Dermatology, Acquisition, LFC, Strategy, Beauty, SOLV, Liverpool F.C., Implementation, Vector

Liverpool based Vector Consumer was founded by Matt Banks-Crompton and John Pugh in 2019, with a vision to disrupt the global consumer healthcare space.

Key Points: 
  • Liverpool based Vector Consumer was founded by Matt Banks-Crompton and John Pugh in 2019, with a vision to disrupt the global consumer healthcare space.
  • With the recent acquisitions of globally renowned brands Pura Collagen and Dose & Co, Vector Consumer is set to become a leading voice in the nutritional collagen industry.
  • Vector Consumer will assume all management of the Dose & Co brand from ZURU Edge.
  • With the rapid expansion of its brand portfolio Vector Consumer will carefully and thoughtfully engineer the complimentary agencies of each brand.

Vector Consumer Limited Announces Second Acquisition, Dose & Co

Retrieved on: 
Wednesday, May 1, 2024
Pura, NPD, Dose, Health, Wellness, Human, Female, Dermatology, Acquisition, LFC, Strategy, Beauty, SOLV, Liverpool F.C., Implementation, Vector

Liverpool based Vector Consumer was founded by Matt Banks-Crompton and John Pugh in 2019, with a vision to disrupt the global consumer healthcare space.

Key Points: 
  • Liverpool based Vector Consumer was founded by Matt Banks-Crompton and John Pugh in 2019, with a vision to disrupt the global consumer healthcare space.
  • With the recent acquisitions of globally renowned brands Pura Collagen and Dose & Co, Vector Consumer is set to become a leading voice in the nutritional collagen industry.
  • Vector Consumer will assume all management of the Dose & Co brand from ZURU Edge.
  • With the rapid expansion of its brand portfolio Vector Consumer will carefully and thoughtfully engineer the complimentary agencies of each brand.

DigitCells Unveils Proprietary TWO-D system at AUA 2024, Revolutionizing Pathology Workflows

Retrieved on: 
Tuesday, April 30, 2024
Prostate, American Urological Association, Breast, LIS, Pathology, Intelligence, Digital, Environment, GI, Marie Cassidy, Histology, Acquisition, IMS, AUA, Annual general meeting, Medical director, Dermatology, Overalls, Medical imaging

CHICAGO, April 30, 2024 /PRNewswire-PRWeb/ -- DigitCells, a leading innovator in complete digital pathology solutions and a subsidiary company of GoPath Diagnostics, is excited to announce the launch of its groundbreaking Tissue Workflow Optimization for Digital (TWOD) system for prostate at the upcoming 2024 American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The TWOD system represents a revolutionary leap in pathology workflows, delivering unprecedented efficiency gains and setting a new benchmark in digital pathology."
  • Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics
    The TWOD system streamlines biopsy tissue workflows, significantly enhancing efficiency to meet the demands of today's pathology environment.
  • This process is centrally managed by TWOD's LIS and IMS system which integrates laboratory information and pathology imaging with embedded augmented intelligence and pathology sign-out functions.
  • The TWOD system bridges the gap between histopathology and digital pathology, reducing cost and improving workflow efficiency.

Local Dermatologist from Tareen Dermatology Has Message to Parents About Checking the Safety of Their Teens' Acne Products

Retrieved on: 
Monday, April 29, 2024
Clinique, FDA, Cancer, Interview, Acne, Safety, Health, Marketing, Benzoyl peroxide, Benzene, Parent, Dermatology, Patient, Clearasil

Dr. Mohiba Tareen, a Board-Certified Dermatologist at Tareen Dermatology and leading expert in the field, expressed concerns about the presence of benzene in acne products.

Key Points: 
  • Dr. Mohiba Tareen, a Board-Certified Dermatologist at Tareen Dermatology and leading expert in the field, expressed concerns about the presence of benzene in acne products.
  • Dr. Tareen emphasized the importance of parents checking the safety of their teens' acne products.
  • "It is crucial for parents to be vigilant and informed about the ingredients in skincare products, especially those targeting acne.
  • For more information or to schedule an interview with Dr. Mohiba Tareen, please contact Natalie Borer, Marketing Director at Tareen Dermatology.

EQS-News: Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential

Retrieved on: 
Friday, May 3, 2024
Plasma, EUR, Patient, Helixmith, Dermatology, Growth, Pharmaceutical industry

Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by Viromed for their 1,250,000 patients and is establishing Plasma Care® by Viromed as the benchmark in Germany.

Key Points: 
  • Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by Viromed for their 1,250,000 patients and is establishing Plasma Care® by Viromed as the benchmark in Germany.
  • Viromed Medical AG believes that the use of Plasma Care® by Viromed by the CORIUS Group will have a signal effect for wound treatment in Germany, further accelerating the spread of innovative cold plasma therapy.
  • Uwe Perbandt, CEO of Viromed Medical AG: ”This agreement is a real milestone for the economic success of our company.
  • Through the exclusive use of our pioneering cold plasma therapy in the facilities of the CORIUS Group with its 1,250,000 patients, Plasma Care® by Viromed will play a key role in innovative wound care.

Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer

Retrieved on: 
Wednesday, April 24, 2024
University, CMO, Safety, NDA, Skin, Leo Pharma, Dermatology, Doctor of Philosophy, Freedom, Engineering, Patient, Doctor of Pharmacy, Secukinumab, Psoriasis, Therapy, Celgene, Biotechnology, Chronic kidney disease, Pharmaceutical industry

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the strengthening of its leadership team with the addition of two experienced executives.

Key Points: 
  • Joana Goncalves, MBChB, will serve as Oruka’s Chief Medical Officer, effective April 18, 2024.
  • Dr. Goncalves brings two decades of leadership experience in dermatology clinical development and medical affairs.
  • Oruka also announced that Eugenia Levi, PharmD, will join the company as Vice President of Medical Affairs.
  • Her extensive leadership experience will prove invaluable as we advance our portfolio of potentially best-in-class antibodies and build a high-performing team,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics.